ID   MuM-2C
AC   CVCL_3448
SY   MUM-2C; MUM2C; Mum2C
DR   BTO; BTO:0005299
DR   cancercelllines; CVCL_3448
DR   Cosmic; 1628412
DR   Wikidata; Q54907076
RX   PubMed=12067204;
RX   PubMed=15299072;
RX   PubMed=18689700;
RX   PubMed=22236444;
RX   PubMed=28940260;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=28940260). Originally thought to originate from a female patient with metastatic uveal melanoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00501.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22236444).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000232). It was one of the sources for the STR profile of this entry.
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): CCRID; PubMed=18689700
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 13,18
ST   D19S433: 14,15
ST   D21S11: 30
ST   D2S1338: 19
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1395 ! M14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=12067204; DOI=10.1023/A:1015591624171;
RA   Seftor E.A., Meltzer P.S., Kirschmann D.A., Pe'er J., Maniotis A.J.,
RA   Trent J.M., Folberg R., Hendrix M.J.C.;
RT   "Molecular determinants of human uveal melanoma invasion and
RT   metastasis.";
RL   Clin. Exp. Metastasis 19:233-246(2002).
//
RX   PubMed=15299072; DOI=10.1158/1535-7163.895.3.8;
RA   Qin J.-Z., Stennett L., Bacon P., Bodner B., Hendrix M.J.C.,
RA   Seftor R.E.B., Seftor E.A., Margaryan N.V., Pollock P.M., Curtis A.,
RA   Trent J.M., Bennett F., Miele L., Nickoloff B.J.;
RT   "p53-independent NOXA induction overcomes apoptotic resistance of
RT   malignant melanomas.";
RL   Mol. Cancer Ther. 3:895-902(2004).
//
RX   PubMed=18689700; DOI=10.1167/iovs.08-2324;
RA   Folberg R., Kadkol S.S., Frenkel S., Valyi-Nagy K., Jager M.J.,
RA   Pe'er J., Maniotis A.J.;
RT   "Authenticating cell lines in ophthalmic research laboratories.";
RL   Invest. Ophthalmol. Vis. Sci. 49:4697-4701(2008).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=28940260; DOI=10.1002/ijc.31067;
RA   Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M.,
RA   Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C.,
RA   Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A.,
RA   Capes-Davis A.;
RT   "Authentication of M14 melanoma cell line proves misidentification of
RT   MDA-MB-435 breast cancer cell line.";
RL   Int. J. Cancer 142:561-572(2017).
//